WO2026110074 - HETEROCYCLIC RISK INHIBITORS
National phase entry is expected:
Publication Number
WO/2026/110074
Publication Date
28.05.2026
International Application No.
PCT/IB2025/061902
International Filing Date
20.11.2025
Title **
[English]
HETEROCYCLIC RISK INHIBITORS
[French]
INHIBITEURS HÉTÉROCYCLIQUES DE KINASES RIS
Applicants **
RECURSION PHARMACEUTICALS, INC.
Inventors
RAY, Peter Christopher
BESNARD, Jérémy
LOWE, Martin Alexander
ATTON, Holly Victoria
BON, Marta
HIGUERUELO, Alicia Perez
TAOUIL, Adam Kassem
MACIAS, Alba Teresa
Priority Data
2417044.1
20.11.2024
GB
2517433.5
20.10.2025
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 12329 | |
| EPO | Filing, Examination, Granting | 48401 | |
| Japan | Filing, Examination, Granting | 3258 | |
| South Korea | Filing, Examination, Granting | 4246 | |
| USA | Filing, Examination, Granting | 16140 |
Total:
84,374
Contact Us
Abstract[English]
Disclosed are PI3K inhibitors according to formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to treat various diseases, disorders and conditions, such as cancer. (Formula I)[French]
Sont divulgués des inhibiteurs de PI3K selon la formule (I), leurs sels pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques de ceux-ci. Sont également divulgués des procédés d'utilisation de tels composés et compositions pour traiter diverses maladies, troubles et affections, tels que le cancer. (Formule I)